Gail Farfel named CEO of ProMIS Neurosciences effective Sept 19, 2022; Eugene Williams stays Chairman

ProMIS Neurosciences Inc.

Gail Farfel appointed CEO effective Sept 19, 2022; Eugene Williams steps down as CEO but remains Chairman.
Dr. Farfel's base salary $500K (up to $535K after raising $75M), 50% bonus target, 208,334 stock options, $25K sign-on.
Eugene Williams to receive $225K/yr as consultant for 3 years, plus severance on signing release.
Dr. Farfel previously Chief Development Officer at Zogenix; led Fintepla Phase 3 and approvals for Dravet/LGS.

item 1.01 item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Eugene Williams

Chief Executive Officer

PMN · ProMIS Neurosciences Inc.

Effective: 2022-09-12
Successor: Gail Farfel
Filed: September 13, 2022, 7:59 PM ET

Eugene Williams, the Company’s Chief Executive Officer and principal executive officer will step down from his officer position with the Company, effective immediately

Appointed

Gail Farfel

Chief Executive Officer

PMN · ProMIS Neurosciences Inc.

Effective: 2022-09-19
Filed: September 13, 2022, 7:59 PM ET

the Board of Directors (the " Board ") of the Company approved the appointment of Gail Farfel, Ph.D. as the Company’s Chief Executive Officer, effective September 19, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Eugene Williams departed as Chief Executive Officer at ProMIS Neurosciences Inc..

Action: stepped down
Role: Chief Executive Officer

Exact text from the filing

Eugene Williams, the Company’s Chief Executive Officer and principal executive officer will step down from his officer position with the Company, effective immediately

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Gail Farfel was appointed as Chief Executive Officer at ProMIS Neurosciences Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

the Board of Directors (the " Board ") of the Company approved the appointment of Gail Farfel, Ph.D. as the Company’s Chief Executive Officer, effective September 19, 2022.

View on SEC.gov

ProMIS Neurosciences Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-099444

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.